Last reviewed · How we verify

NCT06908915: Nd:YAG

Long Pulse 1064 nm Nd:YAG Laser in the Treatment of Erythematotelangiectatic Rosacea and Other Erythematous Telangiectatic Facial Conditions

Completed NA Last updated 3 April 2025
What this trial tests

NA trial testing Nd:YAG laser 1064 nm in Rosacea, Erythematotelangiectatic in 30 participants. Completed in 4 November 2024.

Timeline
3 March 2023
Primary endpoint
1 November 2023
4 November 2024

Quick facts

Lead sponsorHawler Medical University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date3 March 2023
Primary completion1 November 2023
Estimated completion4 November 2024
Sites1 location across Iraq

Drugs / interventions tested

Conditions studied

Sponsor

Hawler Medical University

Who can join

Adults 32 to 52, any sex, with Rosacea, Erythematotelangiectatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical study is to assess the effectiveness of Nd:YAG laser 1064 nm in the long pulse mode in the treatment of signs of rosacea including the erythema of the face and telangiectasia. The used parameter of this laser was of very low energy (spot size: 5mm, fluence: 4.07 J/Cm2, energy: 800 millijoules (mJ) and frequency: 5 Hz. About 2-3 passes performed in each treatment session. Up to four sessions were performed for each patient with 2 weeks interval) and also its was expected to have minimal adverse effects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Rosacea, Erythematotelangiectatic

Currently open trials in the same condition.

Other Hawler Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06908915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing